3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
2
Psoriasis
1
Prostatic Neoplasms
1
Precancerous Conditions
1
Paget's Disease, Mammary
1
Osteoarthritis
1
Obesity
1
Neoplasms
1
Neoplasm, Residual
1
Fatigue
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Intraductal, Noninfiltrating
1
Cancer Cachexia
1
Breast Carcinoma In Situ
1
Barrett Esophagus
1
Autoimmune Diseases
1
Arthritis, Rheumatoid
1
Aggressive Periodontitis
1
Interventions
Methotrexate
8
Adalimumab
7
Etanercept
5
tocilizumab
4
Rituximab
4
tofacitinib
3
Abatacept
3
olokizumab
2
golimumab
2
Tumor Necrosis Factor Inhibitors
2
Antirheumatic Agents
2
upadacitinib
1
secukinumab
1
sarilumab
1
mavrilimumab
1
baricitinib
1
andecaliximab
1
Vitamin D
1
Vaccines
1
TACI receptor-IgG Fc fragment fusion protein
1
Syringes
1
Sulfasalazine
1
Saline Solution
1
Leflunomide
1
Hydroxychloroquine
1
Herpes Zoster Vaccine
1
Folic Acid
1
Fish Oils
1
Fatty Acids, Omega-3
1
Eicosapentaenoic Acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Arthritis, Rheumatoid
×
Docosahexaenoic Acids
×
Clear all
NCT01351805
2025-12-03
VITAL
Brigham and Women's Hospital
Phase NA
Completed
25,871 enrolled
15 charts